Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Precision BioSciences, Inc. - Common Stock
(NQ:
DTIL
)
4.740
+0.080 (+1.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Precision BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
DTIL Revenue Drops 99%
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Earnings Scheduled For August 7, 2025
August 07, 2025
Via
Benzinga
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
August 06, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
August 04, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
July 23, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
July 16, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’
June 25, 2025
The FDA designation could make Precision eligible for a valuable Priority Review Voucher, while preclinical data showed strong dystrophin restoration across key muscle groups.
Via
Stocktwits
Discover the top movers in Wednesday's pre-market session.
June 25, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 25, 2025
Via
Benzinga
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
June 25, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Sidoti Events, LLC's Virtual May Micro-Cap Conference
May 20, 2025
Via
ACCESS Newswire
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 14, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Earnings Scheduled For May 15, 2025
May 15, 2025
Via
Benzinga
Uncovering Potential: Precision BioSciences's Earnings Preview
May 14, 2025
Via
Benzinga
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
May 08, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
May 07, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 01, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 15, 2025
Via
Benzinga
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
April 15, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
March 26, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Earnings Scheduled For March 26, 2025
March 26, 2025
Via
Benzinga
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
March 21, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
March 20, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Assessing Precision BioSciences: Insights From 4 Financial Analysts
March 19, 2025
Via
Benzinga
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 19, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
March 17, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.